Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature-Reference-Cited by-同舟云学术

Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature

Published:2016-12-15 Issue:24 Volume:128 Page:2824-2833
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kavanagh David¹,McGlasson Sarah²^ORCID,Jury Alexa²,Williams Jac³,Scolding Neil⁴,Bellamy Chris⁵,Gunther Claudia⁶,Ritchie Diane³,Gale Daniel P.⁷,Kanwar Yashpal S.⁸,Challis Rachel¹,Buist Holly⁹,Overell James¹⁰,Weller Belinda³,Flossmann Oliver¹¹,Blunden Mark¹²,Meyer Eric P.¹³,Krucker Thomas¹⁴,Evans Stephen J. W.¹⁵,Campbell Iain L.¹⁶,Jackson Andrew P.²,Chandran Siddharthan³,Hunt David P. J.²³^ORCID

Affiliation:

1. National Renal Complement Therapeutics Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom;

2. Medical Research Council Institute of Genetics and Molecular Medicine and

3. Centre for Clinical Brain Sciences, Edinburgh University, Edinburgh, United Kingdom;

4. Institute of Clinical Neurosciences, University of Bristol, Bristol, United Kingdom;

5. Department of Renal Medicine, University of Edinburgh, Edinburgh, United Kingdom;

6. Department of Dermatology, University Hospital, Technical University Dresden, Dresden, Germany;

7. Centre for Nephrology, Royal Free Hospital, University College London, London, United Kingdom;

8. Feinberg School of Medicine, Northwestern University, Chicago, IL;

9. Department of Cellular Pathology, Royal Victoria Hospital, Newcastle upon Tyne, United Kingdom;

10. Institute of Neurological Sciences, Glasgow University, Glasgow, United Kingdom;

11. Royal Berkshire Hospital, Reading, United Kingdom;

12. Barts and the London National Health Service Trust, London, United Kingdom;

13. Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland;

14. The Scripps Research Institute, La Jolla, CA;

15. London School of Hygiene & Tropical Medicine, London, United Kingdom; and

16. School of Molecular Bioscience, University of Sydney, Sydney, Australia

Abstract

Key Points Type I IFN therapies can cause a dose-dependent TMA. Recombinant type I IFN therapies should be stopped at the earliest opportunity in patients who develop TMA.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/24/2824/1358090/blood715987.pdf

Reference43 articles.

1. Drug-induced thrombotic microangiopathy: a systematic review of published reports;Al-Nouri;Blood,2015

2. Syndromes of thrombotic microangiopathy;George;N Engl J Med,2014

3. Adverse drug reactions;Pirmohamed;BMJ,1998

4. Type I interferon dysregulation and neurological disease;McGlasson;Nat Rev Neurol,2015

5. Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature;Zuber;Medicine (Baltimore),2002

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological Impact of Type I Interferon Dysregulation;Rare Neurodegenerative Disorders - New Insights [Working Title];2024-07-31

2. The brain microvasculature is a primary mediator of interferon-α neurotoxicity in human cerebral interferonopathies;Immunity;2024-07

3. Lupus Nephritis Patterns and Response to Type I Interferon in Patients With DNASE1L3 Mutations: Report of Three Cases;American Journal of Kidney Diseases;2024-07

4. IL-6–mediated endothelial injury impairs antiviral humoral immunity after bone marrow transplantation;Journal of Clinical Investigation;2024-04-01

5. Thrombotic Microangiopathy as a Life-Threatening Complication of Long-Term Interferon Beta Therapy for Multiple Sclerosis: Clinical Phenotype and Response to Treatment—A Literature Review;Journal of Clinical Medicine;2024-03-11